Biotechnology is advancing on multiple simultaneous technology frontiers — mRNA platform technology extending from vaccines to therapeutics, RNA interference achieving durable gene silencing across multiple disease areas, CRISPR gene editing approaching clinical validation in rare genetic disease, antibody discovery platforms generating next-generation bispecific and trispecific antibodies, and AI-driven drug discovery compressing development timelines. The companies that most effectively translate these platform technologies into commercially successful products will define the competitive hierarchy of biotechnology for the next decade.

Regeneron's VelocImmune antibody discovery platform has generated more FDA-approved antibody therapies than any other platform in history. Alnylam's RNAi technology has produced five approved products across metabolic and neurological disease. Vertex's CASGEVY — the first approved CRISPR gene editing therapy — represents the commercial validation of gene editing as a therapeutic modality. Amgen's half-life extension technology and bispecific antibody platform are the foundation of its next-generation oncology pipeline.

This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.

Emerging Technologies Assessed in This Report Include:
• mRNA Therapeutics — extending platform beyond vaccines to oncology, rare disease, and cardiology
• RNA Interference — durable gene silencing across metabolic and neurological disease
• CRISPR Gene Editing — clinical validation in rare genetic disease with CASGEVY approval
• Bispecific and Multispecific Antibodies — next-generation oncology and immunology
• Antibody-Drug Conjugates — precision targeting with cytotoxic payload delivery
• CAR-T Cell Therapy — expanding from hematology to solid tumors
• AAV Gene Therapy — rare disease treatments and manufacturing scale-up
• AI Drug Discovery — compressing target identification and lead optimization
• Plasma Fractionation Innovation — next-generation immunoglobulin therapies

Companies Analyzed in This Report:
Alnylam Pharmaceuticals
Amgen
Biogen
BioNTech
CSL Behring
Genmab
Gilead Sciences
Moderna
Regeneron
Vertex Pharmaceuticals

The Analysis of Each Company Includes:
• Strategic Directions and Corporate Priorities
• Financial Performance and Revenue Breakdown
• SWOT Analysis
• Technology and Innovation Programs
• M&A, Partnerships and Alliances
• Market Positioning and Competitive Strategy
• Integration Roadmap and 2030 Outlook

Topics Covered
• mRNA Therapeutics — Platform Extension and Commercial Pipeline
• RNA Interference — Approved Products and Pipeline 2025
• CRISPR Gene Editing — Clinical Programs and Commercial Outlook
• Bispecific and Multispecific Antibodies — Platform Strategies
• Antibody-Drug Conjugates — Biotech vs. Pharma Competition
• CAR-T Cell Therapy — Next-Generation and Solid Tumor Programs
• AAV Gene Therapy — Manufacturing and Cost of Goods
• AI Drug Discovery — Platform Productivity and Pipeline Impact
• Investment and Partnership Landscape 2023–2025